Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 800-991-7 | CAS number: 1427388-03-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- Between February the 12th 2002 and March 15th 2002
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in accordance with generally accepted scientific principles, possibly with incomplete or methodological deficiencies, which do not affect the quality of relevant results.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 002
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- no
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- 86273-46-3
- Cas Number:
- 86273-46-3
- IUPAC Name:
- 86273-46-3
- Reference substance name:
- -
- EC Number:
- 451-690-9
- EC Name:
- -
- Reference substance name:
- 2-Propenoic acid, 2-[2-(ethenyloxy)ethoxy]ethyl ester
- IUPAC Name:
- 2-Propenoic acid, 2-[2-(ethenyloxy)ethoxy]ethyl ester
- Details on test material:
- - Name of test material (as cited in study report): HBM-AV
- Substance type: Colourless transparent liquid
- Physical state: liquid
- Analytical purity: 99.7%
- Impurities (identity and concentrations): see section 1.2
- Composition of test material, percentage of components: see section 1.2
- Lot/batch No.: FX-IT30-AV
- Expiration date of batch number: 30th June 2002
- Storage condition of test material: Cold storage and protected from light
Constituent 1
Constituent 2
Constituent 3
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan Inc, Atsugi Breeding centre, 795 Shimofurusawa, Atsugi-shi, Kanagawa, Japan
- Age at study initiation: 6 weeks
- Weight at study initiation:
Male: 204g to 228g
Female: 141 to 166g
- Fasting period before study:
- Housing: Animals were housed individually in stainless steel bracket cages for rats (260W x 380D x 180Hmm)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: acclimitised for 7 days prior to experiments
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3 deg C
- Humidity (%): 50 +/- 20%
- Air changes (per hr): 10 or more per hour
- Photoperiod (hrs dark / hrs light): 12 hours light followed by 12 hours of darkness.
IN-LIFE DATES: From: Day 1 Up to: Day 15
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: not stated
- Amount of vehicle (if gavage):
- Justification for choice of vehicle: not stated
- Lot/batch no. (if required): V9K2502
- Purity: not stated
MAXIMUM DOSE VOLUME APPLIED:
10 mL/kg suspensions
DOSAGE PREPARATION (if unusual):
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: - Doses:
- 1024, 1280, 1600, 2000 and 2500 mg/kg suspensions
- No. of animals per sex per dose:
- 1024 mg/kg Male: 5 Female: 5
1280 mg/kg Male: 5 Female: 5
1600 mg/kg Male: 5 Female: 5
2000 mg/kg Male: 5 Female: 5
2500 mg/kg Male: 5 Female: 5 - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: days 1, 2, 3, 4, 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs at 30 minutes, 1, 3, 6 hours and then daily up to day 15. - Statistics:
- Mean values and standard deviations of body weights obtained in this study were calculated for each group. The LD50 and 95% confidence limit for each group were calculated by Probit method.
Results and discussion
Effect levelsopen allclose all
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 790 mg/kg bw
- 95% CL:
- >= 1 494 - <= 2 160
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 2 026 mg/kg bw
- 95% CL:
- >= 1 725 - <= 2 614
- Mortality:
- All of the deaths were observed on day 2. Deaths occurred in 1 male and 2 females at 1600 mg/kg, 1 male an 3 females at 2000 mg/kg and all males and females at 2500 mg/kg. Meanwhile, no death occurred in the 1024 and 1280 mg/kg group.
The Ld50 values were calculated by Probit method. As a result, the LD50 of HBM-AV values were 2026 mg/kg (95% confidence limit: 1725-2614 mg/kg) for males and 1790 mg/kg (95% confidence limit: 1494-2160 mg/kg) for females. - Clinical signs:
- other: In the 1024 mg/kg group, no abnormal findings were noted through the observation period in both males and females. In the 1280 mg/kg group, at 3-6 hours after administration, decreased locomotor activity was observed in 3 males and 3 females. In the 1600
- Gross pathology:
- In all animals that died, stomach distension and dark redness of glandular stomach were observed, but in the animals that survived, no special changes were noted in males and females in any groups.
- Other findings:
- not reported
Any other information on results incl. tables
Discussion:
HBM-AV was administered by gavage to SD [Crj:CD(SD)] rats (five rats of each sex group) at doses of 1024, 1280, 1600, 2000 and 2,500 mg/kg. After administration, observations were performed for 15 days (including the day of treatment) and the potential acute toxicity and the LD50 of HBM-AV were studied.
All of the deaths in any groups were observed on day 2. Deaths occurred in 1 males and 2 females at 1600 mg/kg, 1 male and 3 females at 2000 mg/kg and all males and females at 2500 mg/kg. Meanwhile, no death occurred in the 1024 and 1280 mg/kg group.
The LD50 values were calculated by Probit method. As a result, the LD50 values of HBM-AV were 2026 mg/kg (95% confidence limit: 1725 -2614 mg/kg) for males and 1790 mg/kg (95% confidence limit: 1494 -2160 mg/kg) for females.
At clinical signs, in 1280 mg/kg or higher groups decreased locomotor activity and abnormal gait were observed in both males and females at 3 -6 hours after administration. In 2000 mg/kg or higher groups, prone position, panting, sedation and hypothermia were observed in either males or females at 6 hours, and in severe cases of these symptoms, animals resulted in death. But in the surviving animals., these symptoms disappeared quickly. These symptoms were considered to be caused by administration of the test substance. Meanwhile in the 1024 mg/kg group, no abnormal findings were noted through the observation period in both males and females.
The body weights of all surviving animals in each group increased satisfactorily throughout the observation period.
At necropsy, in all animals that died, stomach distension and dark redness of glandular stomach considered congestion/hemorrhage were observed. But in the animals that survived, no special changes were noted in both males and females in any groups.
Based on the above results, the LD50 of HBM-AV was estimated to be 2026 mg/kg for males and 1790 mg/kg for females under the conditions of the study.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Based on the results as detailed in the discussion above, the LD50 of HBM-AV was estimated to be 2026mg/kg for males and 1790 mg/kg for females under the conditions of the study. The substance VEEA can be classified as Acute Tox 4.
- Executive summary:
HBM-AV was administered by gavage to SD [Crj:CD(SD)] rats (five rats of each sex/group) at doses of 1024, 1280, 1600, 2000 and 2500 mg/kg. After administration, observations were performed for 15 days (including the day of treatment) and the potential acute toxicity and the LD50 of HBM-AV were studied.
All of the deaths were observed on day 2 after administration. Deaths occurred in 1 male and 2 females at 1600 mg/kg, 1 male and 3 females at 2000 mg/kg. Meanwhile, no death occurred in the 1024 nor the 1280 mg/kg group.
Based on the results of the test VEEA is classified as harmful according to the EU classification and labelling system..
At clinical signs, in 1280 mg/kg or higher groups decreased locomotor activity and abnormal gait were observed in both males and females at 3 - 6 hours after administration. In 2000 mg/kg or higher groups, prone position, panting sedation and hypothermia were observed in either males or females. Meanwhile, in the 1024 mg/kg group, no adnormal findings were noted through the obsevration period.
The body weights of all survivng animals in each group increased satisfactorily throughout the observation period.
At necropsy, in all animals that died, stomach distention and dark redness of glandular stomach were observed. But in the animals that survived, no special changes were noted in both males and females in any groups.
Based on the above results, the LD50 of HBM-AV was estimated to be 2026mg/kg for males and 1790 mg/kg for females under the conditions of the study.
The substance VEEA can be classified as R22 harmful according to the EU labelling and classification guidelines.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.